---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173803"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:04:16.058987+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Seres stockholders approve increase in authorized shares from 200M to 240M at annual meeting

## Summary
- All three Class II director nominees elected: Berenson, Kender, and Fraser.
- Amendment to increase authorized common shares to 240M approved with 98.4% of votes cast in favor.
- Ratification of PwC as auditor for FY2023 approved with 99.8% of votes cast in favor.
- Advisory vote on executive compensation passed with approximately 99.4% of votes cast in favor.

## SEC filing metadata
- accession: 0001193125-23-173803
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/0001193125-23-173803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523173803/d518244d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173803
- JSON: https://secwatch.observer/filing/0001193125-23-173803.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.